Latin America Hemodynamic Monitoring System Market is expected to reach USD 171.37 million by 2026 from USD 103.44 million in 2018, at a CAGR of 6.6% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below.
The Hemodynamic Monitoring System market is a highly concentrated market which includes key players and local players. The market has witnessed increased various strategic developments owing to favourable market scenario. The market has a prominent growth in upcoming years due to growing demand for the hemodynamic monitoring system, booming across critical care, increasing government focuses towards critical care infrastructure and services, cases of cardiovascular diseases and diabetes and continuous technological advancements in hemodynamic monitoring systems.
The market has witness developments in terms of merger and acquisitions, partnerships or product launches to enhance the product portfolio to meet the rising demand of innovative monitoring technology in hemodynamic. For instance, In April, 2019 Edwards Lifesciences Corporation (US) Completes Acquisition of CAS Medical Systems, Inc. (US). CAS Medical Systems, Inc. a medical technology organization that is dedicated for non-invasive brain and tissue oxygenation monitoring.
EDWARDS LIFESCIENCES CORPORATION (US) dominated the hemodynamic monitoring system market and accounts for the highest market share in 2018 which is followed by getinge AB (Sweden), ICU MEDICAL, INC. (US), CHEETAH MEDICAL INC (US), DRÄGERWERK AG & CO. KGAA. (Germany ) and LIDCO (UK) The other key players existing in the market includes CNSYSTEMS MEDIZINTECHNIK GMBH (Austria), DELTEX MEDICAL (UK) FUJIFLIMS Corporation (Japan) , GENERAL ELECTRIC COMPANY (US), KONINKLIJKE PHILIPS N.V. (Netherlands), NI MEDICAL (Israel ), OSYPKA MEDICAL GMBH (Germany), USCOM (Australia) and Others. EDWARDS LIFESCIENCES CORPORATION:
Edwards Lifesciences Corporation headquartered in California, US was founded in 1958. The company is engaged in providing innovative medical devices for heart disease, critical care and surgical monitoring. The company is providing products in nine products categories annuloplasty rings, catheters, surgical heart valves, transcatheter heart valves, hemodynamic monitoring, bovine pericardial patches, pressure monitoring, accessories and instruments, support. The market focused category lies under hemodynamic monitoring. The company has three operating Business categories Trans catheter heart valve therapy, surgical heart valve therapy, critical care. The market focused category lies under critical care’s category. The company has increased focus on critical care category as its profit share is increased to 18.12% in 2018 from 17% market share in 2017. The company is having 13,000 working employees in 2018. The company global Revenue 2018 is USD 3722.8 Million. The company has global presence in Europe ,America , Asia pacific, Middle East and Africa regions. The company is continuously engaged in strategic relationship to enhance the production and manufacturing of the hemodynamic monitoring system such as, In April 2019, EDWARDS LIFESCIENCES CORPORATION received FDA clearance for its HemoSphere advanced monitoring platform. It is designed for blood flow monitoring and to assist in timely clinical decisions. It is next generation of hemodynamic monitoring system. It is wireless-enabled that allows to collect hemodynamic data thus helping in evaluating and improving the patient care.
It has its global networks through direct sales representatives and distributors in the Latin America. The company has various subsidiaries such as Edwards Lifesciences Pte. Ltd(Singapore), Edwards Lifesciences Ltd (Thailand), Edwards Lifesciences Private Ltd(India), Edwards Lifesciences Inc (Canada), Edwards Lifesciences Sdn. Bhd. (Malaysia), Edwards Lifesciences CardiAQ LLC(US), Edwards Lifesciences Czech Republic s.r.o. (Czech Republic), Edwards Lifesciences Mexico S.A. de C.V.(US),Edwards Lifesciences Macchi Ltda (US), Edwards Lifesciences Italia SpA(Italy) and others .
Getinge AB is headquartered in Gothenburg, Sweden founded in 1904. The company is engaged in manufacturing of medical device and services to provide better patient outcomes and can enhance health economics. Getinge AB offers various innovative solutions for better Life such as Life Science, Hospital and Services. In. The market focused category lies under Hospital. The company operates through three business segments which include Acute Care Therapies, Surgical Workflows and Life Science. The market focused category lies under Acute Care Therapies category. The company has increased focus on critical care category as its profit share is increased to 4.5% as compared to previous year. The company is having 10,515 working employees in 2018. 2018, the revenue of the company obtained in 2018 was USD 2,689.69 Million. During the fiscal year 2018.
Out of the total revenue, the acute care therapy contributed 54.00%, Surgical Workflows 37.00% and 9.00% of share for the life science. The research and development investment of the company have expanded USD 72.28 million in 2017 to USD 76.89 million in 2018. The company is continuously engaged in strategic relationship to enhance the production and manufacturing of the hemodynamic monitoring system such as, In February, 2018 The company got U.S. Food and Drug Administration (FDA) 510(k) clearance for its PulsioFlex Monitoring System and PiCCO Module. The PulsioFlex is a hemodynamic monitoring system providing cardiac output. It is manufactured to measure and monitor the blood pressure and used for the hemodynamic monitoring. The rising consumers of the medical and surgical devices in healthcare sectors corresponding the treatments of diseases and manufacturing of the pharmaceutical products raised the consumption of hospital products
The company has global presence in Europe, America , Asia pacific, Middle East and Africa regions. The company has wide geographic presence in North America, South America, Europe, Asia Pacific, Middle East & Africa. It operates through its subsidiaries such as Getinge Korea Co Ltd (South Korea), Getinge Group Taiwan Co. Ltd (Taiwan), Getinge Holding GmbH (Germany), Getinge India Pvt Ltd (India), Getinge UK Ltd (U.K) and others.
ICU MEDICAL headquartered in California, US was founded in mid-1984s. The company is engaged in designing and manufacture high-technology systems in the field of Infusion Consumables, IV Solutions, Infusion Systems, Critical Care, Other. . ICU MEDICAL offers various innovative solutions for better Life such as ONOCOLOGY, critical care, speciality, Infusion Therapy. The market focused category lies under critical care category The company operates through five business segments which include Infusion Consumables, IV Solutions, Infusion Systems, Critical Care, Other. The market focused category lies under critical care category The company has increased focus on critical care category as its revenue increased to USD 53.5 Million in 2018 from USD 50 Million in 2017. In 2018, the total employees of the company were more than 8,100, whereas the revenue of the company obtained in 2018 was USD 1,400.04 Million. The rising consumers of the Hemodynamic Monitoring System in critical care sectors for the treatments of diseases raised hemodynamic monitoring system the consumption.
The company has global presence in Europe, America, Middle East and Africa regions. It has its global established offices are in Netherland, U.S., India, Taiwan and UAE, whereas company distribute for hemodynamic monitoring system and other products worldwide. It operates through its subsidiaries such as Medical Australia Limited (Australia), ICU Medical de Mexico S.A. de C.V. (U.S.), ICU Medical Europe S.r.l.(U.K.), Icu Medical Slovakia S.R.O. V Likvidacii (Slovakia), Neo Care GmbH (Germany).
Latin America Hemodynamic Monitoring System Market – Industry Trends and Forecast to 2026